載入...
Focus on Nintedanib in NSCLC and Other Tumors
Nintedanib is a new triple angiokinase inhibitor that potently blocks the proangiogenic pathways mediated by vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and fibroblast growth factor receptors. Evidence about its efficacy in addition to second-line chemothe...
Na minha lista:
| 發表在: | Front Med (Lausanne) |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5165233/ https://ncbi.nlm.nih.gov/pubmed/28066768 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2016.00068 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|